A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2028-10-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and
preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the
treatment of adult patients with B-cell malignancies.